Therapy Areas: Cardiovascular
Oligomerix Names Erhardt as Chief Medical Officer
20 May 2020 - - US-based Oligomerix, Inc., a company developing small molecule therapeutics targeting tau for Alzheimer's disease and related neurodegenerative disorders, has appointed William Erhardt, M.D as its chief medical officer, the company said.

With over 20 years in the pharmaceutical industry, Erhardt brings extensive experience in clinical drug development.

Erhardt is a seasoned pharmaceutical executive with broad global experience in medical, clinical operations and development.

He is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development as well as all aspects of medical product support.

His background is complimented by significant organizational design and leadership experience.

Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse.

He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children's National Medical Center.

In addition, Dr. Erhardt has served as a Staff Fellow at the US Food and Drug Administration. Dr. Erhardt is a Fellow of the American Academy of Pediatrics.

Most recently, Dr. Erhardt was senior vice president, Head of Clinical Development and Operations at Pfizer, Inc. responsible for design, conduct and reporting of Pfizer's global Clinical Development portfolio.

He oversaw Pfizer's Clinical, Clinical Sciences, Clinical Project Management and Study Management functions as well as Pfizer's Internal Phase I Clinical Research units in New Haven and Brussels, Belgium.

In this role, Dr. Erhardt was responsible for all Clinical Development functions for a portfolio of 350 clinical studies across the Cardiovascular, Metabolic Neuroscience, Vaccines, Immunology and Inflammation and Rare Disease therapeutic areas.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer's disease and related dementias by targeting tau self-association.

The company's drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program.

Oligomerix's small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream.

The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programmes. 


Related Headlines